Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

AGNPF

Algernon Pharmaceuticals (QB) (AGNPF)

Algernon Pharmaceuticals Inc (QB)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:AGNPF
FechaHoraFuenteTítuloSímboloCompañía
03/06/202205:03Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)USOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
22/02/202205:04Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)USOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
11/02/202107:00InvestorsHub NewsWireAlgernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study ProtocolUSOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
04/06/202011:41InvestorsHub NewsWireAlgernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19USOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
27/05/202014:14Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)USOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
13/04/202008:44InvestorsHub NewsWireAlgernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) HowardUSOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
13/03/202007:40InvestorsHub NewsWireAlgernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and EmergencyUSOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
06/03/202007:32InvestorsHub NewsWireAlgernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for CoronavirusUSOTC:AGNPFAlgernon Pharmaceuticals Inc (QB)
 Showing the most relevant articles for your search:USOTC:AGNPF

Su Consulta Reciente

Delayed Upgrade Clock